JP2021533779A5 - - Google Patents
Info
- Publication number
- JP2021533779A5 JP2021533779A5 JP2021507761A JP2021507761A JP2021533779A5 JP 2021533779 A5 JP2021533779 A5 JP 2021533779A5 JP 2021507761 A JP2021507761 A JP 2021507761A JP 2021507761 A JP2021507761 A JP 2021507761A JP 2021533779 A5 JP2021533779 A5 JP 2021533779A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- linker
- antigen
- optionally
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765095P | 2018-08-16 | 2018-08-16 | |
| US62/765,095 | 2018-08-16 | ||
| PCT/US2019/046705 WO2020037150A2 (en) | 2018-08-16 | 2019-08-15 | Engineered bispecific proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533779A JP2021533779A (ja) | 2021-12-09 |
| JP2021533779A5 true JP2021533779A5 (enExample) | 2022-08-22 |
| JP7397063B2 JP7397063B2 (ja) | 2023-12-12 |
Family
ID=69525976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507761A Active JP7397063B2 (ja) | 2018-08-16 | 2019-08-15 | 操作された二重特異性タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220017634A1 (enExample) |
| EP (1) | EP3850007A4 (enExample) |
| JP (1) | JP7397063B2 (enExample) |
| KR (1) | KR20210064199A (enExample) |
| CN (1) | CN112839955A (enExample) |
| AU (1) | AU2019320803A1 (enExample) |
| BR (1) | BR112021002730A2 (enExample) |
| CA (1) | CA3109763A1 (enExample) |
| EA (1) | EA202190542A1 (enExample) |
| IL (1) | IL280882A (enExample) |
| MA (1) | MA53616A (enExample) |
| MX (1) | MX2021001711A (enExample) |
| SG (1) | SG11202101273VA (enExample) |
| WO (1) | WO2020037150A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| PH12022551598A1 (en) | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| WO2023038803A2 (en) * | 2021-08-25 | 2023-03-16 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| WO2023085779A1 (ko) * | 2021-11-09 | 2023-05-19 | 한양대학교 산학협력단 | Fc 변이체를 포함하는 이종이합체 및 이의 제조방법 |
| JP2025503437A (ja) * | 2021-12-17 | 2025-02-04 | デナリ セラピューティクス インコーポレイテッド | ポリペプチド操作、ライブラリー、ならびに操作されたｃｄ９８重鎖及びトランスフェリン受容体結合ポリペプチド |
| US12011489B2 (en) | 2022-03-30 | 2024-06-18 | Christopher Key | Compositions and methods for treating inflammatory disease |
| KR20250058123A (ko) | 2022-07-29 | 2025-04-29 | 리제너론 파마슈티칼스 인코포레이티드 | 항-TfR:페이로드 융합 및 이의 사용 방법 |
| CA3263388A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | VIRAL PARTICLES RETRIBUTED TO TRANSFERRIN RECEPTOR 1 |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| CN118221803A (zh) * | 2022-12-19 | 2024-06-21 | 深圳科兴药业有限公司 | 异源二聚体Fc融合蛋白及其用途 |
| IL326018A (en) | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
| US20250049896A1 (en) | 2023-07-28 | 2025-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1697520A2 (en) * | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| SG11201404751UA (en) * | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| EP3594240B1 (en) * | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| CA2944402A1 (en) * | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| HUE057952T2 (hu) * | 2015-06-24 | 2022-06-28 | Hoffmann La Roche | Anti-transzferrin receptor antitestek testreszabott affinitással |
| CN107531788B (zh) * | 2015-06-24 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 对her2和血脑屏障受体特异性的三特异性抗体及使用方法 |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| CA2998174A1 (en) * | 2015-09-15 | 2017-03-23 | Amgen Inc. | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
| CN110506055A (zh) * | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| SG11201907422RA (en) * | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| WO2018237338A1 (en) * | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| CR20200129A (es) * | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| WO2019094576A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Bace-tau bispecific antibodies |
| WO2019094608A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| TW201934573A (zh) * | 2018-01-10 | 2019-09-01 | 美商戴納立製藥公司 | 轉鐵蛋白受體結合性多肽及其用途 |
| WO2019246071A1 (en) * | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
-
2019
- 2019-08-15 WO PCT/US2019/046705 patent/WO2020037150A2/en not_active Ceased
- 2019-08-15 JP JP2021507761A patent/JP7397063B2/ja active Active
- 2019-08-15 BR BR112021002730-0A patent/BR112021002730A2/pt not_active IP Right Cessation
- 2019-08-15 KR KR1020217007602A patent/KR20210064199A/ko not_active Withdrawn
- 2019-08-15 MX MX2021001711A patent/MX2021001711A/es unknown
- 2019-08-15 MA MA053616A patent/MA53616A/fr unknown
- 2019-08-15 CA CA3109763A patent/CA3109763A1/en active Pending
- 2019-08-15 AU AU2019320803A patent/AU2019320803A1/en not_active Abandoned
- 2019-08-15 CN CN201980066244.0A patent/CN112839955A/zh active Pending
- 2019-08-15 EA EA202190542A patent/EA202190542A1/ru unknown
- 2019-08-15 SG SG11202101273VA patent/SG11202101273VA/en unknown
- 2019-08-15 EP EP19849330.6A patent/EP3850007A4/en not_active Withdrawn
-
2021
- 2021-02-11 US US17/174,231 patent/US20220017634A1/en not_active Abandoned
- 2021-02-15 IL IL280882A patent/IL280882A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533779A5 (enExample) | ||
| JP2021510162A5 (enExample) | ||
| AU2015357053B2 (en) | Domain-exchanged antibody | |
| JP2023514371A5 (enExample) | ||
| KR101522954B1 (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
| JP2023085476A5 (enExample) | ||
| JP2021534220A5 (enExample) | ||
| JP2024150674A5 (enExample) | ||
| IL269395B2 (en) | Immunoconjugation of anti-PD-1 antibody with IL-2 or IL-15 mutation | |
| JP2019533441A5 (enExample) | ||
| JP2018537966A5 (enExample) | ||
| JP2018504092A5 (enExample) | ||
| JP2021521781A5 (enExample) | ||
| JP2023554500A5 (enExample) | ||
| JP2022512234A5 (enExample) | ||
| JP2024504372A5 (enExample) | ||
| JP2023545707A5 (enExample) | ||
| JP2026035742A5 (enExample) | ||
| JPWO2022102768A5 (enExample) | ||
| US20250277055A1 (en) | Bi- or multi-specific antibody | |
| JPWO2019216436A1 (ja) | 抗体の抗原結合領域を含み、生理活性ペプチドを融合する人工タンパク質 | |
| JP2024500354A5 (enExample) | ||
| JP2024546129A5 (enExample) | ||
| JP2024534118A5 (enExample) | ||
| JP2024534824A5 (enExample) |